Getting old stinks, mostly because with age comes a variety of ailments. Currently, companies that develop rejuvenation biotechnology interventions have to target individual diseases to gain FDA approval. However, a recent Lifespan.io article discussed the National Institutes of Aging’s (NIA) funding of new clinical trials against aging itself. This is an important distinction because the trials are for interventions that directly affected the root causes of age-related diseases rather than the disease itself.
NIA Looks to Combat Aging with New Clinical Trials
Rather than targeting an individual disease, funding will promote broader research related to aging.
Feb 25, 2021
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
